REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors (RETRIEVE-BT)
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors - A Prospective Multicenter Feasibility Study
Bladder cancer is the most common malignancy of the urinary tract, and approximately 75% of cases are non-muscle invasive (NMIBC) at diagnosis. The standard treatment is transurethral resection of the bladder tumor (TURBT). En bloc resection (EBR-T), in which the tumor is removed in one intact piece rather than fragmented, offers superior pathological specimen quality and may reduce the need for repeat resections. However, extracting the intact specimen from the bladder through the urethra remains a critical technical challenge, particularly for larger tumors.
CURTIS (Urotech GmbH) is a CE-marked retrieval device consisting of a hydrophilic-coated bag that can be opened and closed via a handpiece, enabling controlled capture and safe transurethral extraction of the resected tumor specimen.
This study aims to evaluate the technical feasibility of CURTIS-assisted intact specimen retrieval following en bloc transurethral resection of primary NMIBC. The central question the study seeks to answer is: in what proportion of cases can CURTIS successfully retrieve an intact en bloc resected bladder tumor, and what is the maximum tumor size for which intact retrieval remains feasible?
연구 개요
상세 설명
Here is the Detailed Description for ClinicalTrials.gov:
Study Design The RETRIEVE-BT Trial is a prospective, multicenter, single-arm, non-randomized feasibility study conducted at multiple urological centers. No control group or randomization is applied, as the study is designed to characterize the technical performance of the CURTIS device under real-world clinical conditions rather than to test a comparative efficacy hypothesis.
The CURTIS Device CURTIS (Urotech GmbH, Achenmühle, Germany) is a CE-marked medical device specifically developed for transurethral retrieval of intact bladder tumor specimens following en bloc resection. The device consists of a hydrophilic-coated retrieval bag that can be opened and closed via a handpiece, enabling controlled capture and safe transurethral extraction of the resected specimen. It is used within its approved intended purpose as defined by EU MDR 2017/745.
Surgical Procedure All procedures are performed under general or spinal anesthesia. En bloc transurethral resection is carried out using a standard resectoscope with an appropriate electrode (e.g., bipolar hook, J-electrode, or needle electrode). A circumferential incision is made in healthy urothelium approximately 3-5 mm lateral to the visible tumor margin, followed by en bloc dissection at the submucosal or muscularis propria level. Once the specimen is fully detached from the bladder wall, CURTIS-assisted retrieval is attempted according to the manufacturer's instructions for use. If retrieval with CURTIS is unsuccessful, conversion to an alternative extraction method is performed at the surgeon's discretion and documented.
Data Collection and Follow-up Data are collected prospectively via an electronic Case Report Form (eCRF). Intraoperative variables recorded include retrieval success or failure, reason for failure if applicable, total procedure time, and dedicated retrieval time. Resected specimens are processed by the local pathology department according to institutional standards; pathological variables include specimen dimensions, muscularis propria presence, pathological T-stage, histological grade (WHO 2022), and resection margin status. Postoperative complications are documented according to the Clavien-Dindo classification until hospital discharge. No additional study-specific outpatient follow-up visits are required.
Statistical Approach This is a pilot feasibility study; the statistical approach is primarily descriptive. The primary endpoint will be reported as an observed proportion with exact 95% Clopper-Pearson confidence interval. A predefined technical feasibility rate of ≥80% is the threshold indicating clinical utility. Secondary endpoints will be analyzed descriptively. A threshold analysis will be applied to identify the maximum tumor size associated with successful intact retrieval.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Yannic T PD Dr. Volz, M.D.
- 전화번호: +4989440071357
- 이메일: yannic.volz@med.uni-muenchen.de
연구 장소
-
-
-
Nuuk, 그린란드, 3900
- Department of Surgery, Queen Ingrid's Hospital
-
연락하다:
- Jørgen B Jensen
- 이메일: jb@skejby.net
-
-
-
-
-
Aarhus, 덴마크, 8200
- Department of Urology, Aarhus University Hospital, Aarhus
-
연락하다:
- Pernille S Kingo
- 이메일: pernking@rm.dk
-
Roskilde, 덴마크, 4000
- Zealand University Hospital, Roskilde
-
연락하다:
- Juan L. Vasquez
- 이메일: julv@regionsjaelland.dk
-
-
-
-
Bavaria
-
Augsburg, Bavaria, 독일, 86156
- Urologie, Universitätsklinikum Augsburg
-
연락하다:
- Roman Mayr, M.D., Prof.
- 이메일: roman.mayr@uk-augsburg.de
-
Erlangen, Bavaria, 독일, 91504
- Universtitätsklinikum Erlangen
-
연락하다:
- Christian Fiebig, M.D.
- 이메일: Christian.Fiebig@uk-erlangen.de
-
Munich, Bavaria, 독일, 80639
- Urologie, Barmherzige Brüder Krankenhaus München
-
연락하다:
- Alexander Prof. Karl, M.D., Prof.
- 이메일: Alexander.Karl@barmherzige-muenchen.de
-
부수사관:
- Theresa Kahl, M.D.
-
Munich, Bavaria, 독일, 81377
- Urologische Klinik und Poliklinik, LMU Klinikum
-
연락하다:
- Yannic Volz, M.D.
- 이메일: yannic.volz@med.uni-muenchen.de
-
Munich, Bavaria, 독일, 81675
- Urologische Klinik, Klinikum Rechts der Isar
-
연락하다:
- Michael Straub, M.D.
- 이메일: michael.straub@tum.de
-
부수사관:
- Fabian Horné, M.D.
-
Nuremberg, Bavaria, 독일, 90419
- Klinik für Urologie, Klinikum Nürnberg, Campus Nord
-
연락하다:
- Gloria Zeitler, M.D.
- 이메일: Gloria.Zeitler@klinikum-nuernberg.de
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age ≥18 years at the time of enrollment
- Suspected primary non-muscle invasive bladder cancer (NMIBC; stage pTa or pT1) based on cystoscopic assessment, with no radiological or clinical evidence of muscle-invasive disease
- Solitary or multiple bladder tumors with an estimated largest diameter of ≤50 mm based on flexible or rigid cystoscopic assessment (or cross-sectional imaging if available)
- Clinical indication for elective transurethral resection of the bladder tumor, planned to be performed as en-bloc resection
- Written informed consent obtained prior to any study-related procedure
- Ability to understand the study procedures and willingness to comply with study requirements
Exclusion Criteria:
- Known or clinically suspected muscle-invasive bladder cancer (MIBC; cT2 or higher) based on cystoscopy or imaging
- Recurrent bladder tumor (prior history of bladder tumor resection within the past 24 months)
- Active untreated urinary tract infection at the time of surgery (requiring postponement and re-evaluation)
- Uncorrectable coagulopathy or anticoagulation that cannot be safely paused perioperatively
- Severe urethral stricture precluding standard resectoscope passage
- Inability to provide written informed consent (e.g., due to cognitive impairment or language barrier without translation support)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: En-Bloc Retriever Arm
En-bloc resection and retrieval of the tumor with CURTIS device
|
After successful en-bloc resection, the tumor is retrieved using the novel retrieval device, where the tumor is catched with a bag and removed through the urethra
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Technical Feasibility Rate of CURTIS-Assisted Intact Specimen Retrieval
기간: Intraoperatively (single assessment at the time of specimen retrieval during the index surgical procedure)
|
Proportion of enrolled patients in whom the CURTIS device enables complete, intact retrieval of the en-bloc resected bladder tumor specimen without fragmentation within the bladder or urethra.
A case is classified as a technical success if the entire resected specimen is extracted through the urethra in one piece using the CURTIS device.
Cases requiring conversion to an alternative retrieval method (e.g., piecemeal extraction, Ellik evacuator, endoscopic bag) are classified as technical failures.
|
Intraoperatively (single assessment at the time of specimen retrieval during the index surgical procedure)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Retrievable Tumor Size
기간: Intraoperatively (measured at time of specimen retrieval)
|
Largest tumor diameter (in mm) at which successful intact retrieval using CURTIS was achieved, used to define a clinically meaningful upper size limit for CURTIS-assisted EBR-T.
|
Intraoperatively (measured at time of specimen retrieval)
|
|
Proportion of Specimens Containing Muscularis Propria (Detrusor Muscle)
기간: Perioperative/Periprocedural
|
Proportion of retrieved specimens containing detrusor muscle on pathological examination.
|
Perioperative/Periprocedural
|
|
Proportion of Specimens Permitting Complete Pathological T-Stage Assessment
기간: Perioperative/Periprocedural
|
Proportion of retrieved specimens allowing complete pathological T-stage assessment (pTa/pT1/pT2+).
|
Perioperative/Periprocedural
|
|
Proportion of Specimens Permitting Histological Grading
기간: Perioperative/Periprocedural
|
Proportion of retrieved specimens permitting grading according to WHO 2022 classification.
|
Perioperative/Periprocedural
|
|
Proportion of Specimens Permitting Resection Margin Assessment
기간: Perioperative/Periprocedural
|
Proportion of retrieved specimens permitting assessment of horizontal and vertical resection margin status.
|
Perioperative/Periprocedural
|
|
Total Procedure Time
기간: Intraoperatively (during the index surgical procedure)
|
Time from cystoscope insertion to complete specimen extraction and withdrawal of all instruments.
|
Intraoperatively (during the index surgical procedure)
|
|
Retrieval Time
기간: Intraoperatively (during the index surgical procedure)
|
Time from completion of en-bloc resection (detachment of tumor from bladder wall) to complete specimen extraction through the urethra.
|
Intraoperatively (during the index surgical procedure)
|
|
Perioperative Complication Rate (Clavien-Dindo Classification)
기간: From start of procedure until hospital discharge, up to 30 days postoperatively
|
All intraoperative and postoperative complications occurring from the start of the procedure until hospital discharge, up to 30 postoperative days, classified according to the Clavien-Dindo classification system.
|
From start of procedure until hospital discharge, up to 30 days postoperatively
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Yannic T Volz, M.D., Urologische Klinik und Poliklinik, LMU Klinikum München
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 26-0559
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .